Marksans Pharma Income Statement

Quarterly

Yearly

home icon
The current prices are delayed, login to your account to see live prices.
LOGIN
202120222023
EBITDA3463010
EBIT3102560
Earning Per Share546
Expenses1,0371,2321,513
Net Profit239187265
Net Profit Margin171314
Operating Profit Margin252022
Profit Before Tax302248338
Dividends Per Share000
Operation Revenue1,3831,5331,911

Peer Comparison (in ₹.Cr.)

CompanyYearEBITEBITDANet ProfitNet WorthProfit Before Tax
2023008,560.84NA9,408.43
2023002,835.49NA4,038.35
202300372.90NA385.50
202300103.87NA140.39
20221,257.602,182.90978.507,628.101,190
The EBITDA of Marksans Pharma is 0 as of 3/1/2024
home icon
The current prices are delayed, login to your account to see live prices.
LOGIN
20182019202020212023
Operating Activities5027233179237
Investing Activities-39-13-60-45-259
Financing Activities3-21-114-15198
Others00000
Net Cash Flow15-760118176

Peer Comparison (in ₹.Cr.)

CompanyYearOperating ActivitiesInvesting ActivitiesFinancing ActivitiesNet Cash Flow
20234,959.33-7,943.682,376.07-608.28
20203,068.45104.04-2,948.82223.67
2018312.42-884.38502.63-69.33
2020140.90-44.50-38.5557.85
2017640-498.50-177.50-36
The cash flow from Operating Activities of Marksans Pharma is 237 as of 3/1/2024